Stock Events

Stock Events

ProSomnus Common Stock 

$0.47
0
+$0+0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
0.27
0.82
1.37
1.92
Expected EPS
1.695129
Actual EPS
N/A

Financials

7.26%Profit Margin
Profitable
2018
2019
2020
2021
2022
2023
14.49BRevenue
1.05BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OSA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Resmed
RMD
Mkt Cap36.04B
ResMed Inc. is a leading competitor in the sleep apnea market, offering CPAP machines and other products that directly compete with ProSomnus's sleep apnea solutions.
Zimmer Biomet
ZBH
Mkt Cap19.92B
Zimmer Biomet Holdings, Inc. provides various medical devices including those for sleep disorders, competing in the broader sleep apnea treatment market.
Medtronic
MDT
Mkt Cap116.33B
Medtronic plc offers a range of medical devices for conditions including sleep apnea, making it a competitor through its respiratory and monitoring solutions.
Koninklijke Philips N.V.
PHG
Mkt Cap26.17B
Koninklijke Philips N.V. is known for its sleep therapy and respiratory care products, directly competing with ProSomnus in the sleep apnea device market.
Inspire Medical Systems
INSP
Mkt Cap2.13B
Inspire Medical Systems, Inc. specializes in implantable solutions for sleep apnea, offering a direct alternative to ProSomnus's oral appliances.
Five Point LLC
FPH
Mkt Cap851.91M
Fisher & Paykel Healthcare Corporation Limited is a leading supplier of CPAP equipment and other respiratory care products, competing in the sleep apnea market.
Smith & Nephew
SNN
Mkt Cap15.61B
Smith & Nephew plc operates in the medical technology market with products that can be used in treating various conditions, including sleep disorders, indirectly competing with ProSomnus.
Stryker
SYK
Mkt Cap136.19B
Stryker Corporation, while known for its orthopaedic devices, also offers products that can be used in the treatment of sleep disorders, positioning it as a competitor.
Globus Medical
GMED
Mkt Cap8.16B
Globus Medical, Inc. focuses on musculoskeletal solutions but its expansion into medical devices for various conditions puts it in indirect competition with ProSomnus.
Boston Scientific
BSX
Mkt Cap149.24B
Boston Scientific Corporation develops medical devices for a variety of conditions, including sleep apnea, through its neuromodulation and other health solutions, making it a competitor.

About

Prosomnus Sleep Technologies, Inc. designs, manufactures, and markets sleep apnea therapy devices for dentists to treat patients diagnosed with obstructive sleep apnea. The company was incorporated in 2016 and is based in Pleasanton, California.
Show more...
CEO
Employees
136
Country
US

Listings

0 Comments

Share your thoughts

FAQ

What is ProSomnus Common Stock stock price today?▼
The current price of OSA is $0.47 USD — it has increased by +0% in the past 24 hours. Watch ProSomnus Common Stock stock price performance more closely on the chart.
What is ProSomnus Common Stock stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ProSomnus Common Stock stocks are traded under the ticker OSA.
What is ProSomnus Common Stock revenue for the last year?▼
ProSomnus Common Stock revenue for the last year amounts to 14.49B USD.
What is ProSomnus Common Stock net income for the last year?▼
OSA net income for the last year is 1.05B USD.
How many employees does ProSomnus Common Stock have?▼
As of April 02, 2026, the company has 136 employees.
In which sector is ProSomnus Common Stock located?▼
ProSomnus Common Stock operates in the Manufacturing sector.
When did ProSomnus Common Stock complete a stock split?▼
The last stock split for ProSomnus Common Stock was on October 04, 2007 with a ratio of 2:1.